Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;21(8):567-568.
doi: 10.1038/s41571-024-00896-w.

NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype?

Christopher Nevala-Plagemann  1 , Ignacio Garrido-Laguna  2
Affiliations

NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype?

Christopher Nevala-Plagemann et al. Nat Rev Clin Oncol. 2024 Aug.
No abstract available

PubMed Disclaimer

References

    1. Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817–1825 (2011). - DOI - PubMed
    1. Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691–1703 (2013). - DOI
    1. Wainberg, Z. A. et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet 402, 1272–1281 (2023). - DOI - PubMed
    1. Roy, A. C. et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann. Oncol. 24, 1567–1573 (2013). - DOI - PubMed
    1. Wang-Gillam, A. et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387, 545–557 (2016). - PubMed

MeSH terms

LinkOut - more resources